GlaxoSmithKline Biologicals and Aeras Global TB Vaccine Foundation Partner to Develop New TB Vaccine
October 19, 2005 - GlaxoSmithKline Biologicals (GSK Biologicals) and the Aeras Global TB Vaccine Foundation (Aeras) today announced a new public-private partnership to develop GSK Biologicals' tuberculosis candidate vaccine Mtb72F/AS02A, which has shown promising results in preclinical studies. In addition, the vaccine has shown a good safety and immunogenicity profile in early-stage clinical trials conducted by GSK Biologicals. TB causes 2 million deaths a year, and is a leading cause of death amongst people with AIDS in the developing world.
June 26, 2005 - Intercell AG and Statens Serum Institut (SSI) announced today that their joint project for the development of a new prophylactic tuberculosis vaccine has gained the support of the Aeras Global TB Vaccine Foundation. Aeras, an organization funded by the Bill and Melinda Gates Foundation, specializes in the development of novel TB vaccines with the aim of controlling the disease in developing countries.
May 3, 2005 - The Aeras Global TB Vaccine Foundation of Bethesda, MD and The University of California, Los Angeles (UCLA) announced today that the two organizations had executed a non-exclusive license for a tuberculosis vaccine technology developed at UCLA.
April 26, 2005 - Denmark today became the first European country to support the Aeras Global TB Vaccine Foundation's efforts to develop a new, effective tuberculosis vaccine with announcements of new financial commitments and scientific partnerships. The agreements, announced today in Copenhagen at an update on TB vaccine development, strengthen Denmark's continuing role in the fight against TB.
March 29, 2005 - The Aeras Global TB Vaccine Foundation of Bethesda, Maryland and Statens Serum Institut (SSI) of Copenhagen, Denmark, today announced a new collaboration on the pre-clinical and clinical development of SSI's tuberculosis (TB) vaccine, HyVac4.